K2 Capital Acquisition 3Q 2026: Net income $1.09M — 10-Q Summary

K2 Capital Acquisition reported net income of $1.09M for 3Q 2026, driven by $1.3M in interest from Trust Account investments, offset by $188,449 in expenses. This contrasts with a loss of $76.02K in the prior year. Trust Account investments totaled $141.3M, and the company continues its search for a target business combination.

Original reporting
Published Nov 13, 2026, 10:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
K2 Capital Acquisition 3Q 2026: Net income $1.09M — 10-Q Summary — source image
Decision brief

The 30-second read

$KTWONeutralLow
01

Why it matters

The disclosed net income of $1.09 M and cash of $771 k are modest, indicating limited immediate trading opportunities. Investors will likely focus on the SPAC's progress in finding a target rather than the current financials.

02

Market read

The filing is a routine earnings disclosure for a micro‑cap SPAC with no immediate catalyst, resulting in low trading relevance.

03

What to watch

Potential future merger activity or changes in market sentiment toward SPACs could amplify the impact of this filing.

Relevance 5/10Novelty 5/10Timing: post‑market filing

Background

K2 Capital Acquisition Corp (KTWO) is a special purpose acquisition company that has not yet commenced operations or identified a merger target. The 10‑Q filing provides the first quarterly financial snapshot.

Company-level read

Ticker impact

$KTWONeutralHigh confidence
Context

K2 Capital Acquisition Corp filed its 10‑Q reporting a net income of $1.09 M for Q3 2026, the first public disclosure of these quarterly results.

Expected impact

likely minimal pressure as investors digest the small profit and low cash position

Evidence & confidence

The numbers are modest (profit under $2 M, cash under $1 M) and the SPAC has not yet identified a target, so no catalyst for a significant price move is present.

Market effects

Limited impact on the broader SPAC sector; the filing reflects typical early‑stage SPAC financials.

No discernible regional effect; the SPAC is US‑listed and the news is company‑specific.

Minimal global relevance; the filing does not affect macro or sector trends.

Counterpoint

If the SPAC secures a high‑value target soon, the modest cash balance could be seen as a catalyst for upside.

Key entities

  • K2 Capital Acquisition Corp

    US‑listed SPAC (ticker KTWO) reporting Q3 2026 results.

Related articles

$SBCHigh

Why SBC Medical Stock Skyrocketed on Friday

SBC Medical Group (NASDAQ:SBC) shares rose 37% after reporting Q3 revenue of $59M, up 35% YoY, and announcing an AI partnership with NeuroBrain Dynamics. The company added 36 clinics, increasing total locations to 293, and saw a 9% rise in patient visits. Operating income surged 66% to $26M, with a 45% operating margin.

$BTOMedAI 8/10

B2Gold Earnings Call Signals Lower Costs and Growth

B2Gold Corp. reported Q3 earnings with strong production, lower cost guidance, and positive free cash flow. The company produced 193,000 ounces of gold, reduced all-in sustaining cost guidance by over $100 per ounce, and generated $48 million in free cash flow. Revenue reached $836 million, supported by higher gold prices. The company also highlighted growth projects and shareholder returns.

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.